OverviewSuggest Edit

Crescendo Biologics is a provider of human VH antibody fragment therapeutics created to optimize antibodies and a transgenic mouse which produces heavy chain only antibodies. The Company develops potent, multi-functional Humabody, therapeutics in oncology with a proprietary pipeline focus on CB307, a unique targeted T-cell engager. It uses its VH fragment discovery platform to advance in-house development programs in inflammation and oncology, using transgenic mice.

TypePrivate
Founded2007
HQBabraham, GB
Websitecrescendobiologics.com

Latest Updates

Employees (est.) (Jan 2020)45(-18%)
Revenue (FY, 2018)£7.5 M(+316%)

Key People/Management at Crescendo Biologics

Theodora Harold

Theodora Harold

CEO
Philip Bland-Ward

Philip Bland-Ward

CDO
Julia Tilson

Julia Tilson

Interim COO
Brian McGuinness

Brian McGuinness

VP, Business Development
Show more

Crescendo Biologics Office Locations

Crescendo Biologics has an office in Babraham
Babraham, GB (HQ)
Meditrina Building 260 Babraham Research Campus
Show all (1)

Crescendo Biologics Financials and Metrics

Summary Metrics

Founding Date

2007

Crescendo Biologics total Funding

$116.2 m

Crescendo Biologics latest funding size

$70 m

Time since last funding

2 years ago

Crescendo Biologics investors

Crescendo Biologics's latest funding round in April 2018 was reported to be $70 m. In total, Crescendo Biologics has raised $116.2 m
Show all financial metrics

Crescendo Biologics Revenue

Embed Graph
View revenue for all periods
Crescendo Biologics's revenue was reported to be £7.51 m in FY, 2018
GBP

Revenue (FY, 2018)

7.5m

Gross profit (FY, 2018)

7.5m

Gross profit margin (FY, 2018), %

100%

Net income (FY, 2018)

(1.8m)

EBIT (FY, 2018)

(2.2m)

Cash (31-Dec-2018)

24.8m
GBPFY, 2016FY, 2017FY, 2018

Revenue

758.3k1.8m7.5m

Gross profit

758.3k1.8m7.5m

Gross profit Margin, %

100%100%100%
GBPFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.3m894.8k2.1m331.6k3.0m2.7m4.3m7.0m24.8m

Accounts Receivable

530.0k704.1k

Current Assets

2.4m950.9k2.9m766.0k6.2m10.7m5.8m9.8m28.5m
GBPFY, 2015FY, 2016FY, 2017FY, 2018

Cash From Operating Activities

(5.2m)(4.7m)(7.2m)167.3k

Cash From Investing Activities

(4.9m)(175.1k)(365.2k)(418.3k)

Cash From Financing Activities

9.8m3.9k18.1m

Net Change in Cash

(321.9k)(4.9m)(7.6m)17.8m
GBPY, 2018

Revenue/Employee

131.7k

Financial Leverage

1.1 x
Show all financial metrics

Crescendo Biologics Online and Social Media Presence

Embed Graph

Crescendo Biologics News and Updates

Invitation du Dr James Legg, vice-président de la recherche et du développement chez Crescendo Biologics et président de la conférence d'immuno-oncologie de cette année

LONDRES, August 23, 2018 /PRNewswire/ -- La conférence d'immuno-oncologie de 2018 de SMi se déroulera à Londres, au Royaume-Uni, le 26 et le 27 septembre. Elle offrira aux participants l'occasion inédite de venir écouter des experts renommés qui leur feront part de leur expertise et de...

Crescendo Biologics Blogs

Diverse human VH antibody fragments with bio-therapeutic properties from the Crescendo Mouse

Diverse human VH antibody fragments with bio-therapeutic properties from the Crescendo Mouse View Publication

New Biotechnology publication validates Crescendo Biologics’ platform as it moves towards the clinic

New Biotechnology publication validates Crescendo Biologics’ platform as it moves towards the clinic View PDF

PMLiVE: A Snapshot of Crescendo Biologics

PMLiVE: A Snapshot of Crescendo Biologics View article

Crescendo Biologics Reaches Fifth Milestone in its Strategic Collaboration with Takeda

Crescendo Biologics Reaches Fifth Milestone in its Strategic Collaboration with Takeda View PDF
Show more

Crescendo Biologics Frequently Asked Questions

  • When was Crescendo Biologics founded?

    Crescendo Biologics was founded in 2007.

  • Who are Crescendo Biologics key executives?

    Crescendo Biologics's key executives are Theodora Harold, Philip Bland-Ward and Julia Tilson.

  • How many employees does Crescendo Biologics have?

    Crescendo Biologics has 45 employees.

  • What is Crescendo Biologics revenue?

    Latest Crescendo Biologics annual revenue is £7.5 m.

  • What is Crescendo Biologics revenue per employee?

    Latest Crescendo Biologics revenue per employee is £166.8 k.

  • Who are Crescendo Biologics competitors?

    Competitors of Crescendo Biologics include Cyteir Therapeutics, Harbour BioMed and Tmunity Therapeutics.

  • Where is Crescendo Biologics headquarters?

    Crescendo Biologics headquarters is located at Meditrina Building 260 Babraham Research Campus, Babraham.

  • Where are Crescendo Biologics offices?

    Crescendo Biologics has an office in Babraham.

  • How many offices does Crescendo Biologics have?

    Crescendo Biologics has 1 office.